ATAI
BEARISH
$3.69
Live
AtaiBeckley Inc. · NASDAQ
Target $13.45
(+264.6%)
$1.15
52W Range
$6.75
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 16, 2026
Market cap
$1.34B
P/E
N/A
ROE
-390.0%
Profit margin
N/A
Debt/Equity
0.02
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
ATAI's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 1/9 indicates extreme operational weakness, and the absence of an Altman Z-Score (with negative profitability and massive losses) raises significant bankruptcy risk. Despite a strong analyst consensus of 'strong_buy' and a high target price of $13.45, the company exhibits no profitability, negative margins, and a 620.8% YoY EPS decline, with earnings surprises consistently negative. The stock trades at an inflated Price/Sales of 327.77 and a Price/Book of 6.04, suggesting extreme overvaluation relative to fundamentals. Insider selling in the last six months further undermines confidence in management's view of the company's prospects.
Key Strengths
Analyst consensus is strongly bullish with a $13.45 target price
High market cap ($1.34B) suggests relative scale within biotech
Extremely high 1-year return (+165.5%) indicates strong momentum
Strong 3-year return (+212.7%) reflects historical investor enthusiasm
High current and quick ratios (11.74 and 11.49) suggest strong liquidity
Key Risks
Piotroski F-Score of 1/9 signals severe financial distress and operational failure
Negative ROE (-389.98%) and ROA (-30.75%) indicate deep unprofitability
Operating margin of -3588.09% reflects catastrophic cost inefficiency
Insider selling of $0.15M in the last 6 months signals bearish sentiment
No revenue or earnings growth data available, with massive negative EPS trends
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
8
Weak
10
15
10
5
0
AI Verdict
High Risk
Key drivers: Piotroski F-Score of 1/9, Negative profitability across all metrics, No growth or earnings stability, Insider selling, Extreme valuation multiples
Confidence
90%
Value
10/100
Ref P/E, PEG, Graham Number
Positives
- High market cap provides some scale
- Strong liquidity (current/quick ratios)
Watchpoints
- Price/Sales of 327.77 is astronomically high
- Price/Book of 6.04 is inflated
- No Graham Number or intrinsic value available
- No earnings to support valuation
Future
15/100
Ref Growth rates
Positives
- Analyst target price of $13.45 implies strong growth expectations
- High 1-year return suggests momentum
Watchpoints
- No revenue or earnings growth data
- Negative EPS growth (-620.8% YoY)
- Most recent Q/Q EPS growth at -517.9%
- Consistently negative earnings surprises
Past
10/100
Ref Historical trends
Positives
- Historical 3-year return of +212.7%
- 52-week high of $6.75 indicates prior strength
Watchpoints
- 5-year return of -81.0% reflects long-term underperformance
- Consistent earnings misses over 20 quarters
- Average surprise of -528.4% in last 4 quarters
- Negative margins and losses in all periods
Health
5/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Low debt/equity ratio (0.02)
- High current and quick ratios (11.74, 11.49)
Watchpoints
- Piotroski F-Score of 1/9 indicates severe financial distress
- No Altman Z-Score available, but negative ROE and margins suggest distress risk
- Negative operating cash flow and free cash flow
- Massive losses and negative profitability
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength of 0/100
- No history of dividend payments
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.69
Analyst Target
$13.45
Upside/Downside
+264.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ATAI and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ATAI
AtaiBeckley Inc.
Primary
|
-81.0% | +212.7% | +165.5% | -20.3% | -7.0% | +8.8% |
|
HROW
Harrow, Inc.
Peer
|
+422.2% | +56.8% | +53.0% | -4.1% | -2.7% | +1.8% |
|
HCSG
Healthcare Services Group, Inc.
Peer
|
-32.6% | +36.6% | +106.5% | +16.8% | -0.9% | +1.7% |
|
WVE
Wave Life Sciences Ltd.
Peer
|
+12.3% | +73.9% | +1.6% | -8.9% | +8.9% | -8.4% |
|
NVCR
NovoCure Limited
Peer
|
-93.7% | -81.1% | -26.1% | -14.2% | -1.7% | +12.8% |
ATA
AtaiBeckley Inc.
Primary
5Y
-81.0%
3Y
+212.7%
1Y
+165.5%
6M
-20.3%
1M
-7.0%
1W
+8.8%
HRO
Harrow, Inc.
Peer
5Y
+422.2%
3Y
+56.8%
1Y
+53.0%
6M
-4.1%
1M
-2.7%
1W
+1.8%
HCS
Healthcare Services Group, Inc.
Peer
5Y
-32.6%
3Y
+36.6%
1Y
+106.5%
6M
+16.8%
1M
-0.9%
1W
+1.7%
WVE
Wave Life Sciences Ltd.
Peer
5Y
+12.3%
3Y
+73.9%
1Y
+1.6%
6M
-8.9%
1M
+8.9%
1W
-8.4%
NVC
NovoCure Limited
Peer
5Y
-93.7%
3Y
-81.1%
1Y
-26.1%
6M
-14.2%
1M
-1.7%
1W
+12.8%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-7.44
PEG Ratio
N/A
P/B Ratio
6.04
P/S Ratio
327.77
EV/Revenue
267.69
EV/EBITDA
-9.93
Market Cap
$1.34B
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-3588.09%
Gross Margin
N/A
ROE
-389.98%
ROA
-30.75%
Growth
Revenue and earnings growth rates
Revenue Growth
N/A
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.02
Low debt
Current Ratio
11.74
Strong
Quick Ratio
11.49
Excellent
Cash/Share
$0.7
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q3 2025
Revenue
$0.0B
Op. Margin
-3792.7%
Net Margin
-8154.1%
Total Assets
$0.2B
Liabilities
$0.1B
Equity
$0.2B
Debt/Equity
0.50x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
123%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-13
$N/A
2026-03-06
$-1.73
-1441.6% surprise
2025-11-12
$-0.28
-125.3% surprise
2025-08-14
$-0.14
-18.3% surprise
Healthcare Sector Comparison
Comparing ATAI against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-389.98%
This Stock
vs
-88.14%
Sector Avg
+342.5%
(Excellent)
Debt to Equity
0.02
This Stock
vs
2.66
Sector Avg
-99.2%
(Less Debt)
Current Ratio
11.74
This Stock
vs
4.47
Sector Avg
+162.4%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ATAI
AtaiBeckley Inc.
|
BEARISH | $1.34B | - | -390.0% | -% | $3.69 | |
|
HROW
Harrow, Inc.
|
NEUTRAL | $1.34B | - | -8.5% | -1.9% | $35.93 | Compare |
|
HCSG
Healthcare Services Group, Inc.
|
BULLISH | $1.36B | 23.89 | 11.7% | 3.2% | $19.35 | Compare |
|
WVE
Wave Life Sciences Ltd.
|
BEARISH | $1.31B | - | -55.0% | -% | $6.94 | Compare |
|
NVCR
NovoCure Limited
|
BEARISH | $1.38B | - | -38.9% | -20.8% | $12.17 | Compare |
ATAI
AtaiBeckley Inc.
BEARISH
Mkt Cap
$1.3B
P/E
-
ROE
-390.0%
Price
$3.69
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-02 | FEILDING-MELLEN COSMO | Director | Sale | 39,594 | $154,377 |
| 2025-11-05 | FEILDING-MELLEN COSMO | Director | Stock Award | 7,702,990 | - |
| 2025-09-30 | APEIRON INVESTMENT GROUP LTD. | Beneficial Owner of more than 10% of a Class of Security | Stock Award | 2,367,200 | - |
FEILDING-MELLEN COSMO
Director
2026-01-02
39,594 shares
·
$154,377
FEILDING-MELLEN COSMO
Director
2025-11-05
7,702,990 shares
APEIRON INVESTMENT GROUP LTD.
Beneficial Owner of more than 10% of a Class of Security
2025-09-30
2,367,200 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
11 analysts
Needham
2026-03-09
Buy
Buy
HC Wainwright & Co.
2026-03-02
Buy
Buy
Guggenheim
2026-01-20
Buy
Jones Trading
2025-12-23
Buy
Canaccord Genuity
2025-10-22
Buy
Buy
Needham
2025-10-13
Buy
HC Wainwright & Co.
2025-09-23
Buy
Buy
Past News Coverage
Recent headlines mentioning ATAI from our newsroom.
Newest → oldest
No matching news yet.